Physician profile
Gitika Dhillon
NPI 1922249150
$8,281.75
in general payments reported to CMS, 2019-2025
29 companies · $1,596 in 2025
The $1,596 reported for 2025 was more than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $417 · 2020: $376 · 2021: $898 · 2022: $1,475 · 2023: $1,638 · 2024: $1,881 · 2025: $1,596.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,933 · Education: $158 · Consulting Fee: $23.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,933.41 |
| Education | $157.77 |
| Consulting Fee | $23.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,005.52 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $1,096.91 | 2019-2025 | Dupixent |
| Genzyme Corporation | $886.06 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $621.48 | 2019-2025 | Fasenra, Breztri, Tezspire |
| Novartis Pharmaceuticals Corporation | $474.80 | 2019-2025 | |
| Genentech USA, INC. | $437.85 | 2021-2025 | Xolair |
| Grifols USA, LLC | $302.92 | 2021-2025 | Xembify, Gamunex-C |
| Csl Behring | $273.43 | 2021-2025 | Hizentra |
| Optinose US, INC. | $268.96 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $219.25 | 2019-2022 | |
| Pfizer INC. | $217.59 | 2019-2025 | |
| Amgen INC. | $183.43 | 2021-2025 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $182.34 | 2023-2025 | Cuvitru, Takhzyro, Eohilia |
| Abbvie INC. | $169.44 | 2021-2024 | Rinvoq |
| Kowa Pharmaceuticals America, INC. | $148.63 | 2024 | Zoryve |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $140.15 | 2019-2024 | Auvi-Q |
| Incyte Corporation | $103.37 | 2021-2025 | Opzelura |
| Sanofi-Aventis U.S. LLC | $99.95 | 2025 | |
| Alk-Abello, INC | $96.32 | 2019-2024 | Grastek, Ragwitek, Odactra |
| Biocryst US Sales Co., LLC | $72.89 | 2022-2025 | Orladeyo |
| Teva Pharmaceuticals USA, INC. | $49.31 | 2021-2023 | Airduo Digihaler |
| Aimmune Therapeutics, INC. | $48.64 | 2022 | |
| Ars Pharmaceuticals Operations, INC. | $47.07 | 2025 | Neffy |
| Merck Sharp & Dohme LLC | $30.78 | 2021-2023 | |
| Adma Biomanufacturing LLC | $23.76 | 2025 | |
| Lilly USA, LLC | $21.05 | 2025 | Ebglyss |
| Hikma Pharmaceuticals USA | $21.00 | 2023 | Ryaltris |
| Leo Pharma INC. | $19.54 | 2022 | |
| Phadia US INC. | $19.31 | 2024 | Immunocap |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gitika Dhillon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.